Biotech IPOs look strong — with haircuts

One of the many takeaways from BIO2011 was data from Elsevier Business Intelligence showing that biotech IPOs actually are doing quite well — up 42 percent post-IPO. Of course, that’s after many of those initial public offerings took significant price haircuts and remain down from where they originally wanted to be.